Cited by 439Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disorders

The DOI matches its Crossref record; 116 of the 117 references it cites were found in a registry or an index.

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

Open access

Sampson, Uchechukwu K., Fazio, Sergio, Linton, MacRae F.·2012·Current Atherosclerosis Reports

DOI 10.1007/s11883-011-0219-7PMC PMC3697085

Open this paper in CoChat — free account

Abstract

This review captures the existence, cause, and treatment challenges of residual cardiovascular risk (CVR) after aggressive low-density lipoprotein cholesterol (LDL-C) reduction. Scientific evidence implicates low high-density lipoprotein cholesterol (HDL-C) and high triglycerides (TG) in the CVR observed after LDL-C lowering. However, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial with fenofibrate, the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) study with torcetrapib, and the recently terminated Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) study with niacin, do not clearly attribute risk reduction value to HDL-C/TG modulation. The optimum approach to long-term lipid-modifying therapies for CVR reduction remains uncertain. Consequently, absolute risk modulation via lifestyle changes remains the centerpiece of a strategy addressing the physiologic drivers of CVR associated with HDL-C/TG, especially in the context of diabetes/metabolic syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s11883-011-0219-7

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers
Arsenault, B. J., Barter, P. J., DeMicco, D. A., Bao, W., Preston, G. M., LaRosa, J. C., Grundy, S. M., DEEDWANIA, P. C., Greten, H., WENGER, N. K., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.052 · Cited by 36
Retracted
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439

Show all 117 references

Sorted by citations

Items 201–300 of 438

Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials
Frigerio, B., Werba, J. P., Amato, M., Ravani, A. L., Sansaro, D., Coggi, D., Vigo, L., Tremoli, E., & Baldassarre, D. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191213120339 · Cited by 13
Lipid Profiles in Out-of-Hospital Sudden Unexpected Death
Hosadurg, N., Bogle, B. M., Joodi, G., Sadaf, M. I., Pursell, I. W., Mendys, P., Mounsey, J. P., & Simpson, R. J. (2018) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2018.06.010 · Cited by 13
“It may also be indicative of a residual sudden death risk in the community despite adequate control of TC and/or LDL-C levels with medication, as previously suggested.(28) High TG(29) and low HDL(30) levels, the hallmarks of combined dyslipidemia, are established predictors of adverse cardiovascular events, but their…”
Sterol carrier protein 2: A promising target in the pathogenesis of atherosclerosis
Xu, C., Li, H., & Tang, C. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.007 · Cited by 12
“Although statins therapy is effective in improving plasma lipid profile in patients with cardiovascular disease, the residual cardiovascular risk is still representing a challenge worthy of attention.(8,9) Therefore, it is necessary to develop new promising therapeutic strategies aiming to target critical molecules in…”
Background
Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease
Welty, F. K., Hariri, E. H., Asbeutah, A. A., Daher, R., Amangurbanova, M., Chedid, G., Elajami, T. K., Alfaddagh, A., & Malik, A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030071 · Cited by 13
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study
Kim, N. H., Kim, J. Y., Choi, J., & Kim, S. G. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad090 · Cited by 13
High-Density Lipoproteins and Coronary Artery Disease
Schaffer, A., Verdoia, M., Barbieri, L., Aprami, T. M., Suryapranata, H., Marino, P. N., & Luca, G. D. (2013) · Angiology · doi:10.1177/0003319713502253 · Cited by 12
“However, a residual event rate was demonstrated in most trials using statins, ranging from 9% to even 20% according to established target level of LDL-C and dosage of statin.(5,6,15) High-density lipoprotein cholesterol has been identified over the past 60 years as an independent modifier of the atherosclerotic proces…”
Background
Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study
Jiang, J., Zhou, Y.-J., Li, J., Ge, J., Feng, Y., & Huo, Y. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s178318 · Cited by 12
“Both epidemiological and interventional clinical trials have shown a strong association between elevated LDL-C level and cardiovascular events.(4,5) A large observational study (DYSIS-China) showed that although the majority (88.”
Background
Low density lipoprotein-induced lipid accumulation is a key phenomenon of atherogenesis at the arterial cell level
Orekhov, A. N., & Myasoedova, V. A. (2019) · Vessel Plus · doi:10.20517/2574-1209.2018.80 · Cited by 12
“Over the past two decades, data demonstrating the non-linear dependence of the reduction in the risk of atherosclerosis from the therapeutic reduction in total LDL level are widely discussed([52-61]).”
Background
High cardiovascular risk in older patients with opioid use disorder: Differences with the general population
Vallecillo, G., Pedro‐Botet, J., Fernández, S. F., Román, I., Elosúa, R., Camps, A., Torrens, M., & Marrugat, J. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13449 · Cited by 12
Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation
Chan, Y., & Ramji, D. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_2 · Cited by 13
Healthcare resource utilization and costs in working-age patients with high-risk atherosclerotic cardiovascular disease: findings from a multi-employer claims database
Zhao, Z., Zhu, Y., Fang, Y.-T., Ye, W., & McCollam, P. L. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1041966 · Cited by 12
“15, or a pharmacy claim for cilostazol or pentoxifylline; or (4) Patients with diabetes mellitus (250.”
Background
Association between fasting Triglyceride levels and the Prevalence of Asymptomatic Intracranial Arterial Stenosis in a Chinese Community-based Study
Wu, J., Wang, Y., Wang, A., Xie, J., & Zhao, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-24157-w · Cited by 11
Physicochemical Properties of Lipoproteins Assessed by Nuclear Magnetic Resonance as a Predictor of Premature Cardiovascular Disease. PRESARV-SEA Study
Fernández‐Cidón, B., Candás‐Estébanez, B., Gil, M., Amigó, N., Corbella, E., Rodríguez-Sánchez, M. A., Padró‐Miquel, A., Brotons, C., Hernández‐Mijares, A., Calmarza, P., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071379 · Cited by 11
“Premature cardiovascular disease (PVCD) remains an important public health issue and dyslipidemia is the most common risk factor of this condition [1] Patients with premature cardiovascular disease (PCVD) have non-conventional risk factors, both lipid and non-lipid [2,3], which entail a residual cardiovascular risk th…”
Background
Sex difference in the relationship of the Atherogenic index of plasma with coronary artery lesions in diabetes: a cross-sectional study
Hu, Y. P., Wang, X., Luo, C., Zheng, T., & Tian, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-022-01767-y · Cited by 11
“However, the cardiovascular risk remains considerable after LDL-C reduction [29].”
Background
A Potential Role of NFIL3 in Atherosclerosis
Zeng, G.-G., Zhou, J., Jiang, W.-L., Yu, J., Nie, G.-Y., Li, J., Zhang, S., & Tang, C. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102096 · Cited by 11
Downregulation of adipose LPL by PAR2 contributes to the development of hypertriglyceridemia
Huang, Y., Chen, L., Li, L., Qi, Y., Tong, H., Wu, H., Xu, J., Leng, L., Cheema, S. K., Sun, G., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.173240 · Cited by 11
“It also increases the risk of cardiovascular disease even in the presence of optimized LDL cholesterol levels (23).”
Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E–knockout mice
Li, G., Wu, X., Lü, W., Ai, R., Chen, F., & Tang, Z. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-145 · Cited by 11
Emerging biologic therapies for hypercholesterolaemia
Pucci, G., Cicero, A. F. G., Borghi, C., & Schillaci, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1341485 · Cited by 11
“On a greater extent, however, residual risk is determined in many high-risk patients by the failure to reach optimal levels of LDL-C [6].”
Background
Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States
Unni, S. K., Quek, R. G. W., BISKUPIAK, J. E., Lee, V. C., Ye, X., & Gandra, S. R. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.09.008 · Cited by 11
The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology
Pitts, R., & Eckel, R. H. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.65 · Cited by 11
Impact of serum levels of lipoprotein lipase, hepatic lipase, and endothelial lipase on the progression of coronary artery disease
Han, H., Dai, D., Wang, W., Zhu, J., Zhu, Z., Lu, L., & Zhang, R. (2019) · Journal of interventional medicine · doi:10.1016/j.jimed.2019.05.005 · Cited by 11
Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol
Bazarbashi, N., & Miller, M. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1749596 · Cited by 11
Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis
Masson, W. M., Lobo, M., Siniawski, D. A., Molinero, G., Huerin, M. S., & Nogueira, J. P. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00330-8 · Cited by 10
Retargeting the management of hypercholesterolemia – focus on evolocumab
Cicero, A. F. G., Colletti, A., & Derosa, G. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s116679 · Cited by 10
“Then, statins are the first drugs suggested,(2) and it has been estimated that statins are able to reduce atherosclerotic cardiovascular disease (ASCVD) risk by 15%–37%, but residual 60%–80% risk still remains and a significant part of this risk is probably related to an insufficient reduction of LDL-C.(4) Corresponde…”
Influential
Lipids and Lipoproteins in Risk Prediction
Hadjiphilippou, S., & Ray, K. K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.002 · Cited by 10
Summarizing the FIELD study: lessons from a ‘negative' trial
Tsimihodimos, V., Mikhailidis, D. P., & Elisaf, M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.850075 · Cited by 10
“In addition, even in statin-treated patients a residual cardiovascular risk remains that has been partially attributed to the aforementioned lipid abnormalities [8].”
Background
The effect of bergamot polyphenolic fraction in patients with non alcoholic liver steato-hepatitis and metabolic syndrome
Gliozzi, M., Maiuolo, J., Oppedisano, F., & Mollace, V. (2015) · PharmaNutrition · doi:10.1016/j.phanu.2015.11.003 · Cited by 10
siRNA-mediated inhibition of SREBP cleavage-activating protein reduces dyslipidemia in spontaneously dysmetabolic rhesus monkeys
Murphy, B. A., Tadin‐Strapps, M., Jensen, K., Mogg, R., Liaw, A. I., Herath, K. B., Bhat, G., McLaren, D. G., Previs, S. F., & Pinto, S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.015 · Cited by 10
Impact of high triglyceride/high-density lipoprotein cholesterol ratio (insulin resistance) in ST-segment elevation myocardial infarction
Chen, H., Lee, W., Fang, H., Fang, C.-Y., Chen, C.-J., Yang, C., & Wu, C. (2020) · Medicine · doi:10.1097/md.0000000000022848 · Cited by 10
“Different letters (a, b, c, d) associated with different groups indicate significant difference (at 0.05 leve DM=diabetes mellitus, HDL-C=high-density lipoprotein cholesterol, MACE=major adverse cardiac eve concentration of HDL-C.”
BackgroundInfluential
Correction to: Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet
Yoshida, M., Nakamura, K., Miyoshi, T., Yoshida, M., Kondo, M., Akazawa, K., Kimura, T., Ohtsuka, H., Ohno, Y., Miura, D., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01181-7 · Cited by 10
Bibliometric analysis of residual cardiovascular risk: trends and frontiers
Wang, L., Wang, S., Song, C., Yu, Y., Jiang, Y., Wang, Y., & Li, X. (2023) · Journal of Health Population and Nutrition · doi:10.1186/s41043-023-00478-z · Cited by 11
“The third most cited article was a review on residual cardiovascular risk [3].”
Background
Guanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoE−/− Mice Fed High-Fat Diet
Yang, M., Jiao, H., Li, Y., Zhang, L., Zhang, J., Zhong, X., & Xue, Y. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s372143 · Cited by 9
“However, there is still a residual cardiovascular risk after effectively lowering LDL-C levels using statins or combined lipid-lowering strategies.(63,64) Recent studies have shown that inflammation and cholesterol are both pathogenic factors of AS.”
Background
High-density lipoprotein infusion therapy: A review
Brewer, H. B., Schaefer, E. J., Foldyna, B., & Ghoshhajra, B. B. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.009 · Cited by 9
Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy
Wang, Z., Zheng, X., Jiang, Z., Liao, X., & Zhao, S. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.105 · Cited by 9
Effects of 3,4-Dihydroxyacetophenone on the Hypercholesterolemia-Induced Atherosclerotic Rabbits
Zhang, D., Liu, J., Wang, L., Wang, J., Li, W., Baoxiang, Z., Hou, J.-P., & Liu, T. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00710 · Cited by 9
Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management
Salah, A. N., Hashem, A. H., Zaki, M. B., Abulsoud, A. I., Atta, A. M., Elkalla, W. S., Moustafa, H. A. M., El‐Dakroury, W. A., El-Tokhy, F. S., ElBoghdady, J. A., et al. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70163 · Cited by 9
“C) concentrations even with optimized statin treatment remains a concern [221].”
Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension
Kazibwe, R., Jehopio, J., Schaich, C. L., Rikhi, R. R., Mirzai, S., Chevli, P. A., Namutebi, J. H., Chebrolu, S., O'Connor, S., Yeboah, J., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.05.006 · Cited by 12
Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial
Nakao, K., Noguchi, T., Asaumi, Y., Morita, Y., Kanaya, T., Fujino, M., Hosoda, H., Yoneda, S., Kawakami, S., Nagai, T., et al. (2018) · Trials · doi:10.1186/s13063-017-2353-1 · Cited by 7
“Discussion Although the results of many randomized controlled trials using statins have shown the usefulness of LDL-cholesterol-lowering therapy, the extent of coronary artery disease suppression did not exceed approximately 30% [27].”
Background
Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk
Catapano, A. L., Tokgözoğlu, L. S., Silva, A. M. E., & Bruckert, É. (2019) · Atherosclerosis Supplements · doi:10.1016/j.athx.2019.100001 · Cited by 8
“Despite this, there remains a residual risk of CV events with statin treatment in clinical trials, even in patients achieving target LDL-C levels [19,20].”
Background
Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study
Metzner, T., Leitner, D. R., Mellitzer, K., Beck, A., Sourij, H., Stojaković, T., Reishofer, G., März, W., Landmesser, U., Scharnagl, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010193 · Cited by 9
“However, despite substantial reductions in LDL cholesterol with statins and newer lipid-lowering agents, patients continue to experience recurrent major cardiovascular events [4].”
Background
Association between Lipoprotein Subfractions, Hemostatic Potentials, and Coronary Atherosclerosis
Flerin, T. P., Mijovski, M. B., & Jug, B. (2022) · Disease Markers · doi:10.1155/2022/2993309 · Cited by 9
“However, despite aggressive LDL-C lowering, substantial residual atherosclerotic risk remains and may possibly be associated with lipid metabolism derangements not captured by measuring LDLC [4].”
Background
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study
Iwasaki, M., Suzuki, H., Umezawa, Y., Koshida, T., Saito, M., Fukuda, H., Takahara, H., Matsuzaki, K., & Suzuki, Y. (2023) · Medicine · doi:10.1097/md.0000000000032818 · Cited by 10
“Notably, additional treatment with fibrate for high TG was associated with reduced CVD risk independent of the LDL-C level among patients treated with statins.[5,6] Bezafibrate (Beza-F) and fenofibrate (Feno-F) are highly effective in lowering plasma TG levels and moderately effective in raising HDL-C.”
Background
Platelet glycoprotein IIIa Leu33Pro gene polymorphism and coronary artery disease: A meta-analysis of cohort studies
Verdoia, M., Cassetti, E., Schaffer, A., Giovine, G. D., & Luca, G. D. (2014) · Platelets · doi:10.3109/09537104.2014.948839 · Cited by 8
Differential Regulation of Gene Expression by Cholesterol Biosynthesis Inhibitors That Reduce (Pravastatin) or Enhance (Squalestatin 1) Nonsterol Isoprenoid Levels in Primary Cultured Mouse and Rat Hepatocytes
Rondini, E. A., Duniec‐Dmuchowski, Z., Cukovic, D., Dombkowski, A. A., & Kocarek, T. A. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233312 · Cited by 8
“Additionally, despite aggressive statin therapy, certain populations have a high residual risk for CVD (Campbell et al., 2007; Sampson et al., 2012), so alternative lipid-modifying agents are needed.”
Background
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
Kosmas, C. E., Sourlas, A., Silverio, D., Montan, P. D., & Guzman, E. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i11.256 · Cited by 8
A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3
Xiao, Q., Wang, L., Wang, J., Wang, M., Wang, D. W., & Ding, H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102011 · Cited by 8
“TRLs and remnants have been identi ﬁ ed as signi ﬁ cant contributors to the residual cardiovascular risk in patients receiving optimal LDL-lowering medication [8,9].”
Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory Medicine
Kenkre, J. S., Mazaheri, T., Neely, R. D. G., Soran, H., Datta, D. B. N., Penson, P. E., Downie, P., Yates, A. M., Hayden, K., Patel, M., et al. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251315303 · Cited by 8
Association between remnant cholesterol and arterial stiffness: Evidence from NHANES 1999–2018
Lai, T., Liang, Y., Guan, F., Chen, Y., & Hu, K. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104013 · Cited by 7
Association between the atherogenic index of plasma and major adverse cardiovascular events in patients with premature coronary artery disease
Ran, X., Wu, Z., Guo, D., Zhang, S., Liu, L., Chen, S., Song, C., Zhang, C., & Yang, J. (2025) · European journal of medical research · doi:10.1186/s40001-025-02796-w · Cited by 7
“Nevertheless, despite controlling patients’ LDL-C to recommended levels, patients still had residual cardiovascular risk[28].”
Modulation of the Hepatic Lipidome and Transcriptome of Apoe-/- Mice in Response to Smoking Cessation
(2013) · Journal of Liver · doi:10.4172/2167-0889.1000132 · Cited by 7
“Despite extensive clinical research on the association of Low- and High-Density Lipoprotein (LDL and HDL) levels with cardiovascular risk, a proportion of patients optimally treated with statins remain at a high risk [6, 7].”
Background
Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia
Borghi, C., & Cicero, A. F. G. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1262347 · Cited by 7
Fasting ketonuria is inversely associated with coronary artery calcification in non-diabetic individuals
Cho, I. Y., Chang, Y., Sung, E., Kim, Y., Kang, J., Shin, H. C., Wild, S. H., Byrne, C. D., & Ryu, S. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.018 · Cited by 7
Lipid Profile and Atrial Fibrillation: Is There Any Link?
Jiang, Q., Yang, L., Chen, M., Hua, F., & Li, J. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2308272 · Cited by 7
“Statin therapy has been used to reduce the concentration of LDL-C levels [41].”
Background
Effects of a dietary intervention with Mediterranean vs lacto-ovo vegetarian diets on HDL function: Results from the CARDIVEG study
Ronca, A., Pellegrini, N., Pagliai, G., Dinu, M., Manfredini, M., Incerti, M., Favari, E., & Sofi, F. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.11.012 · Cited by 7
The U-shaped association between remnant cholesterol and risk of all-cause and cardiovascular deaths in diabetic adults: Findings from NHANES 1999–2018
Wang, H., Guo, Y., Zhang, H., Wang, X., & Zheng, X. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.011 · Cited by 9
The predictive value of triglyceride-glucose index combined with non–high-density lipoprotein cholesterol in coronary heart disease
Zhang, C., Zhang, H., Yang, Z., Sheng, Y., & Ji, N. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04410-z · Cited by 8
“It has been shown that Non-HDL-C is a better predictor of atherosclerotic cardiovascular events than LDL-C [6].”
Protocatechuic Acid Attenuates Inflammation in Macrophage-like Vascular Smooth Muscle Cells in ApoE−/− Mice
Li, S., Du, Y., Chen, G., Mao, Y., Zhang, W., Kang, M., Zhu, S., & Wang, D. (2025) · Nutrients · doi:10.3390/nu17061090 · Cited by 7
Impact of lipoprotein (a) on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents
Kimura, T., Akahori, H., Tanaka, T., Yanaka, K., Yoshihara, N., Miki, K., Imanaka, T., Asakura, M., & Ishihara, M. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.03.004 · Cited by 7
Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing statin treatment
Sakai, R., Sekimoto, T., Koba, S., Mori, H., Matsukawa, N., Arai, T., Yokota, Y., Sato, S., Tanaka, H., Masaki, R., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.01.004 · Cited by 7
Non‐fasting lipids and cardiovascular disease in those with and without diabetes in Alberta's Tomorrow Project: A prospective cohort study
Weaver, O. R., Ye, M., Vena, J. E., Eurich, D. T., & Proctor, S. D. (2023) · Diabetic Medicine · doi:10.1111/dme.15133 · Cited by 7
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7
Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial
Monguillon, V., Marston, N., Bohula, E. A., Park, J., Kuder, J., Murphy, S. A., Ferrari, G. M. D., Leiter, L. A., Nicolau, J. C., Ebenbichler, C. F., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080999 · Cited by 7
Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients
Taboun, Z., Naik, N., Brown, V., Lin, P., Padarath, M., Hegele, R. A., & Gupta, M. (2023) · CJC Open · doi:10.1016/j.cjco.2023.02.002 · Cited by 6
“Lowering of LDL-C level is fundamental to risk reduction in high-risk patients, including those with ASCVD or diabetes, yet lipid management in high-risk patients remains challenging in Canada and beyond.(11,12) The 2021 CCS lipid guidelines included stronger recommendations for combination LDL-C-lowering therapies in…”
Background
Impact of non-traditional lipid profiles on 1-year vascular outcomes in ischemic stroke patients with prior statin therapy and LDL-C < 100 mg/dL
Kim, H., Kim, J., Lee, J. S., Kim, B. J., Kang, J., Lee, K., Park, J., Kang, K., Lee, S. J., Kim, J. G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-73851-5 · Cited by 6
“While the reduction of LDL-C through statin therapy diminishes a patient’s cardiovascular risk, a residual risk persists even when LDL-C levels are adequately controlled 14 .”
Background
Optimizing Long-term Cardiovascular Risk Stratification: Integrating Biomarkers into the Very High-Risk ASCVD Definition in Asian Patients
Cheng, J., Wang, H., Song, C., Qiao, Z., Bian, X., Yin, D., Feng, L., Zhu, C., Yang, M., Gao, G., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100965 · Cited by 6
“…residual CV risk despite achieving LDL-C targets, incorporating biomarker-based high-risk conditions into the VHR definition may enhance risk stratification and guide more personalized treatment strategies, particularly in diverse populations where current criteria may be insufficient [9,10].”
Thymoquinone (TQ) Inhibits Inflammation and Migration of THP-1 Macrophages: Mechanistic Insights into the Prevention of Atherosclerosis Using In-Vitro and In-Silico Analysis
Huwait, E. A., Al-Gharawi, N., Al-Ghamdi, M. A., Gari, M. A., Prola, A., Pushparaj, P. N., & Gauthaman, K. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44040120 · Cited by 6
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States
Fonseca, A. F., Byrne, H., Laguna-Fernández, A., Itani, T., Studer, R. L., Heo, J., Dillon, A., Ferber, P. C., & Costa‐Scharplatz, M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.519 · Cited by 6
Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China
Wang, Z., Zhang, X., Qu, Y., Zhang, S., Chen, Y., Chen, X., Qi, X., Liu, P., Liu, S., Jiang, S., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01838-8 · Cited by 7
Cardiovascular Disease Risk Across a Spectrum of Adverse Plasma Lipid Combinations by Gender and Glycemic Status
Liu, X., Yang, Y., Kang, F., Li, J., Zhou, M., Ma, X., Yu, T., Zhang, T., & Xue, F. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.058 · Cited by 5
Lipid parameters and vitamin A modify cardiovascular risk prediction by plasma neopterin
Dhar, I., Siddique, S., Pedersen, E. R., Svingen, G. F. T., Lysne, V., Olsén, T., Nilsen, D. W. T., Nordrehaug, J. E., Midttun, Ø., Ueland, P. M., et al. (2020) · Heart · doi:10.1136/heartjnl-2019-316165 · Cited by 6
(Apo)Lipoprotein Profiling with Multi‐Omics Analysis Identified Medium‐HDL‐Targeting PSRC1 with Therapeutic Potential for Coronary Artery Disease
Li, Y., Wang, S., Liu, L., Cai, H., Huang, Y., Gao, M., Zhang, X., Wu, Q., & Qiu, G. (2025) · Advanced Science · doi:10.1002/advs.202413491 · Cited by 6
Remnant cholesterol concentrations best explain the cardiovascular benefit of APOC3 genetic inhibition: A drug target Mendelian Randomization study
Gagnon, É., Gill, D., Burgess, S., & Arsenault, B. J. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf018 · Cited by 5
“36 This residual risk could be attributed to other risk factors not adequately addressed by licenced therapies.”
Body Mass Index, use of Statins or Current Lipidemic Control: Do they Affect Body Fat Distribution in Sedentary Type 2 Diabetes Mellitus?
Solanki, J., Makwana, A., Mehta, H., Desai, C., & Gandhi, P. (2015) · Journal of Obesity and Metabolic Research · doi:10.4103/2347-9906.151755 · Cited by 5
Remnant cholesterol and risk of aortic aneurysm and dissection: a prospective cohort Study from the UK biobank study and mendelian randomization analysis
Zhou, T., Lin, W., Yang, B., Liu, Y., Huang, W., Xie, N., Yang, F., Lin, Z., Hu, Z., Luo, S., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02466-0 · Cited by 5
The effect of bergamot-derived polyphenolic fraction on LDL small dense particles and non-alcoholic fatty liver disease in patients with metabolic syndrome
Ehrlich, J., Gliozzi, M., Carresi, C., Musolino, V., Palma, E., Muscoli, C., Vitale, C., Muscianisi, G., Janda, E., Ragusa, S., et al. (2015) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2015.05.015 · Cited by 5
Influence of Baseline Psychological Health on Muscle Pain During Atorvastatin Treatment
Zaleski, A. L., Taylor, B. A., Pescatello, L. S., Dornelas, E. A., White, C. M., & Thompson, P. D. (2016) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000382 · Cited by 5
How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors
Lee, E. Y., & Yoon, K. (2018) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2018.7.1.1 · Cited by 5
Dyslipidemia and Cardiometabolic Syndrome
Hsiao, Y.-C., & Wu, C. (2021) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2021.1.e2 · Cited by 5
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
Mansoor, T., Nambi, V., Parikh, S. S., Misra, A., Ismayl, M., Sullivan, C., Sperling, L. S., Virani, S. S., Rifai, M. A., Koshy, S. K. G., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00748-7 · Cited by 4
Integrated Analysis of Ferroptosis- and Cellular Senescence-Related Biomarkers in Atherosclerosis Based on Machine Learning and Single-Cell Sequencing Data
qi, X., Cao, S., Chen, J., & yin, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s529581 · Cited by 4
“The key transcription factor for Tfh cells is B-cell lymphoma 6.”
Association of pan-immune-inflammation value and atherogenic index of plasma with chronic coronary syndrome in non-alcoholic fatty liver disease patients
Yu, B., Zhao, J., Zhang, W., Wang, L., Zheng, X. S., Li, X., Yao, Z., Sun, Y., Ren, Z., & Liang, B. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1650319 · Cited by 4
High density lipoprotein subfractions and extent of coronary atherosclerotic lesions: From the cordioprev study
de la Cruz, S., Leon‐Acuña, A., Yubero‐Serrano, E. M., Torres-Peña, J. D., Larriva, A. P. A.-D., Cardelo, M. P., Rangel-Zúñiga, O. A., Luque, R. M., Alcala-Diaz, J. F., Ordovás, J. M., et al. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.06.002 · Cited by 4
“…umbrella of dyslipidemia exists a dramatic heterogeneity and complexity, such as the numerous, and potentially significant lipoprotein subfractions pre-sent in the fasting and postprandial states [9,10], but we lack full understanding of their contributions and informativeness as CHD risk factors.”
Mechanism of Tao Hong Decoction in the treatment of atherosclerosis based on network pharmacology and experimental validation
Li, S., Liu, P., Feng, X., Du, M., Zhang, Y., Wang, Y., & Wang, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1111475 · Cited by 4
Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Menezes, A. D. S., Oliveira, V. M. R., Oliveira, I. C., de Sousa, A. M., Santana, A. J. P., Carvalho, D. P. C., Piai, R. F. P., Matos, F. H., de Paiva, A. M., & Reis, G. B. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175674 · Cited by 4
“considerable residual cardiovascular risk persists [6].”
Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients with Dyslipidemia: A Randomized, Add-on Placebo-Controlled Clinical Trial
Maiti, R., Mohanty, R. R., Dey, A., Maji, S., Padhan, M., & Mishra, A. (2023) · Journal of the American Nutrition Association · doi:10.1080/27697061.2023.2256816 · Cited by 4
Low-density lipoprotein particle profiles compared with standard lipids measurements in the association with asymptomatic intracranial artery stenosis
Vu, T., Yano, Y., Pham, H. K. T., Mondal, R. K., Ohashi, M., Kitaoka, K., Moniruzzaman, M., Torii, S., Shiino, A., Tsuji, A. B., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59523-4 · Cited by 4
Atherogenic index of plasma and cardiovascular outcomes in female patients undergoing percutaneous coronary intervention: insights from a retrospective cohort study
Jiang, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-87281-4 · Cited by 4
Joint exposure to multiple air pollutants and residual cardiovascular risk in hypertension
Li, Y., Hong, W., Wu, J., Wang, J., Liu, S., Yuan, H., Cai, J., Miao, R., Wang, J., & Lu, Y. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.117782 · Cited by 4
Mechanisms and implications of vascular-homing CD8 T cells in atherosclerosis
Su, X., O’Hare, K. A., & Freeman, M. L. (2025) · npj Cardiovascular Health · doi:10.1038/s44325-025-00056-8 · Cited by 6
“Despitethe widespreaduseofstatinstomitigatelipidlevels,atherosclerosis-related mortalityhascontinuedtorise 3,4 , highlighting the need for a more comprehensive treatment approach.”
PCSK9, a novel target for lowering LDL cholesterol: promise and progress
Tavori, H., Fazio, S., & Linton, M. F. (2012) · Clinical Lipidology · doi:10.2217/clp.12.72 · Cited by 4
Self-citation
Current state-of-the-art knowledge on the role of omega-3 fatty acids in the prevention of cardiovascular disease
Kłosiewicz−Latoszek, L., Cybulska, B., & Tyszko, P. Z. (2020) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/126674 · Cited by 4
Proposal for a Multidisciplinary Clinical Approach to Obesity
Rosero, R., Polanco, J. P., Ciro, V., Uribe, A., Manrique, H., & Sánchez, P. E. (2020) · Journal of Medical - Clinical Research & Reviews · doi:10.33425/2639-944x.1185 · Cited by 7
“A single altered value of the lipid profile already classifies the patient as being at moderate risk, which together with the patient’s morphotype may suggest that the patient is at an even greater risk [43].”
Background
PCSK9 Targeting in the Management of Hypercholesterolaemia
Kosmas, C. E., Papakonstantinou, E. J., Carreño, J., Uceta, R. E., Guzman, E., & Sourlas, A. (2023) · EMJ Cardiology · doi:10.33590/emjcardiol/10303462 · Cited by 4
“7 In this regard, the addition of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the lipid-lowering armamentarium was monumental, irrevocably changing the scope of lipid-lowering treatment, and closing the gap in optimal LDL-C reduction.”
Background
Lipid-lowering activity of Cow urine ark in guinea pigs fed with a high cholesterol diet.
Chawda, H. M., Rasiklal, M. D., Baxi, S., Kishorbhai, V. V., & Tripathi, C. R. (2014) · Europe PMC (PubMed Central) · Cited by 4
Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological properties
Lampropoulou, A., Zannis, V. I., & Kypreos, K. E. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.006 · Cited by 3
Non-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a Venezuelan population
Bermúdez, V., Torres, W., Salazar, J. J., Martínez, M. S., Rojas, E., Olivar, L. C., Lameda, V., Ortega, Á., Ramírez, P., Rojas, M., et al. (2018) · F1000Research · doi:10.12688/f1000research.13005.1 · Cited by 4
Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
“Residual risk persists in many individuals, especially those with features of metabolic syndrome (MetS) or diabetes mellitus (DM), suggest - ing the need to address additional lipoprotein abnormalities such as elevated triglycerides (TGs) and TG-rich lipoproteins (TRLs) [ 6, 7 ].”
Walking the VLDL tightrope in cardiometabolic diseases
Kim, M., & Zheng, Z. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.020 · Cited by 4
Association between coexisting hypertension, dyslipidaemia and elevated C reactive protein with cardiovascular disease and mortality: a cross-sectional and longitudinal analysis in a representative cohort of older US adults
Karadimas, T., & Meier, H. C. S. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000455 · Cited by 5
Unveiling Impurities: A Comprehensive RP-HPLC Method for Accurate Atorvastatin Impurity Analysis in Pharmaceuticals Using an Accuracy Profile Approach
Kacemi, M. E., Orche, A. E., Bourakadi, K. E., Benchekroun, Y. H., Echerfaoui, F., Karrouchi, K., Bouatia, M., & Karbane, M. E. (2024) · Journal of AOAC International · doi:10.1093/jaoacint/qsae060 · Cited by 3

Authors: Sampson, U. K., Fazio, S., & Linton, M. F.
Affiliations: Vanderbilt University Medical Center (US)
Corresponding author: Linton, MacRae F.
ORCID: Fazio, Sergio
Linton, MacRae F.
Venue: Current Atherosclerosis Reports
Publisher: Springer Science and Business Media LLC
Published: 2011-11-19
Volume: 14
Issue: 1
Pages: 1-10
ISSN: 1523-3804 (ISSN-L)
1534-6242
DOI: 10.1007/s11883-011-0219-7
PMC: PMC3697085
OpenAlex: W2079979713
Cited by: 439
References: 117
Citations by year: 2026: 37 · 2025: 36 · 2024: 38 · 2023: 50 · 2022: 43 · 2021: 36 · 2020: 34 · 2019: 36 · 2018: 33 · 2017: 25 · 2016: 19 · 2015: 18 · 2014: 15 · 2013: 11 · 2012: 7
FWCI: 1.91
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Current Atherosclerosis Reports (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Heart, Lung, and Blood Institute (R01HL065709, R01HL086988, HL086988, HL105375, HL65709, R01HL105375)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: residual cardiovascular risk, LDL cholesterol lowering, statins, HDL cholesterol, triglycerides, fenofibrate, torcetrapib, nicotinic acid, AIM-HIGH trial, ILLUMINATE trial, diabetes mellitus, metabolic syndrome, lifestyle modification, lipid therapy
MeSH terms: Cardiovascular Diseases, Humans, Life Style, Cholesterol, LDL, Morbidity, Risk Factors, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks